HomeDMYD-B • STO
add
Diamyd Medical AB
Previous close
kr 10.18
Day range
kr 9.91 - kr 10.30
Year range
kr 7.50 - kr 25.00
Market cap
1.38B SEK
Avg Volume
560.95K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Feb 2025info | Y/Y change |
|---|---|---|
Revenue | 86.00K | 230.77% |
Operating expense | 44.69M | 59.86% |
Net income | -44.87M | -53.39% |
Net profit margin | -52.17K | 53.63% |
Earnings per share | — | — |
EBITDA | -44.01M | -60.78% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Feb 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 103.75M | -24.35% |
Total assets | 180.88M | -20.13% |
Total liabilities | 69.35M | 53.23% |
Total equity | 111.53M | — |
Shares outstanding | 104.09M | — |
Price to book | 9.51 | — |
Return on assets | -56.58% | — |
Return on capital | -85.35% | — |
Cash Flow
Net change in cash
| (SEK) | Feb 2025info | Y/Y change |
|---|---|---|
Net income | -44.87M | -53.39% |
Cash from operations | -48.41M | -36.64% |
Cash from investing | -458.00K | 86.82% |
Cash from financing | -635.00K | -203.83% |
Net change in cash | -49.13M | -24.15% |
Free cash flow | -32.72M | -9.70% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
30
